Abstract
Highly Pathogenic Avian Influenza strain H5N1 has caused a multi-state outbreak among US dairy cattle, spreading across 15 states and infecting hundreds of herds since its onset. We rapidly developed and optimized PCR-based detection assays and sequencing protocols to support H5N1 molecular surveillance. Using 214 retail milk from 20 states for methods development, we found that H5N1 concentrations by digital PCR strongly correlated with qPCR cycle threshold (Ct) values, with dPCR exhibiting greater sensitivity. We also found that metagenomic sequencing after hybrid selection was best for higher concentration samples while amplicon sequencing performs best for lower concentrations. By establishing these methods, we were able to support the creation of a statewide surveillance program to test bulk milk samples monthly from all cattle dairy farms within Massachusetts, which remain negative to date. The methods, workflow, and recommendations described here provide a framework for others aiming to conduct H5N1 surveillance efforts.
Competing Interest Statement
P.C.S. is co-founder and shareholder in Sherlock Biosciences and Delve Bio, and is a board member and shareholder of Danaher Corporation. DHO is a co-founder and managing member of Pathogenuity LLC.
Funding Statement
This work was supported by funding from the Howard Hughes Medical Institute (HHMI) Investigator Program (to P.C.S.), the US Centers for Disease Control and Prevention (BAA 75D30122C15113 to P.C.S and PGCoE NU50CK000629 to S.W., L.M., P.C.S, and B.L.M.), and the NIH National Institute of Allergy and Infectious Diseases (GCID U19AI110818 to P.C.S. and D.J.P. and CREID U01AI151812 to P.C.S.). J.A.S. is supported in this project by philanthropic funding from the TED Audacious Project. D.H.O. and W.V. were funded by Heart of Racing and the UW Institute for Clinical and Translational Researchs Pilot Award program. This publication was supported by the Office of Advanced Molecular Detection, Centers for Disease Control and Prevention through Cooperative Agreement Number CK22-2204. The content is solely the responsibility of the authors and does not necessarily represent the official views or policies of the Centers for Disease Control and Prevention or the U.S. government. This study has been approved for public release; distribution is unlimited.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
